国家首个手术机器人国标出炉 告别“一刀切”

Core Insights - The National Healthcare Security Administration (NHSA) issued the "Guidelines for Pricing Projects of Surgical and Treatment Auxiliary Medical Services (Trial)" on January 20, 2026, marking a significant step in regulating and promoting the pricing management of advanced medical technology services in China [1][3] - The guidelines focus on cutting-edge medical technologies, establishing a clear framework with 37 pricing projects, 5 additional charges, and 1 expansion item [1][3] Pricing Framework - The guidelines do not implement a one-size-fits-all pricing model for robotic surgeries but instead create a tiered pricing system based on the robot's involvement in specific surgeries and its clinical value contribution [4] - NHSA will guide local authorities to establish minimum and maximum pricing standards, allowing provinces to set specific coefficients and amounts based on local economic conditions and healthcare fund capabilities [2][4][5] Market Dynamics - As of 2024, domestic surgical robots have captured nearly 50% market share, significantly replacing imports in fields such as orthopedics, neurosurgery, and laparoscopy, with increasing reliability and clinical acceptance [2][5] - Despite this growth, the overall penetration rate of surgical robots in China remains significantly lower than that in developed countries, indicating substantial growth potential in the market [5] - The issuance of the guidelines is seen as a key institutional innovation for advancing precision medicine in China, with expectations that the domestic surgical robot industry will progress from "domestic substitution" to "intelligent advancement" [5]